OLIVER TECHNOW

Oliver Technow is the former CEO of BIOVECTRA Inc., a Charlottetown based, globally operating Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical and biotech companies with full-service solutions for API (active pharmaceutical ingredients) and intermediates. BIOVECTRA operates several facilities in the Maritimes and employees more than 650 highly skilled individuals.

Oliver joined BIOVECTRA in late 2015 as President. He oversaw the divestiture of the company from Mallinckrodt to HIG Capital in 2019 and was appointed its Chief Executive Officer. Under his leadership BIOVECTRA developed into a globally recognized CDMO powerhouse, shifting its offering from small molecules to a full-service, vertically integrated CDMO, supporting clinical and commercial scale across biologics, complex chemistry and advanced modalities.

Oliver has more than 35 years of experience in the global LifeScience’s sector. Prior to joining BIOVECTRA, he held Management roles with Mallinckrodt Pharmaceuticals and Eisai Pharmaceuticals which included responsibilities on the Global level as well as local mandates in Canada, Europe and the USA. Born and raised in Europe, he relocated to North America in 2007 and has lived and worked in both, Canada and the USA since.

Oliver is now operating a consulting company, Morpheus Management Consulting Inc.

Oliver serves as a Chair of the Board of BIOTECanada and is the past chair of the PEI BioAlliance. During his tenure at the PEI BioAlliance he championed the emergence of CASTL (Canadian Alliance for Skills and Training in LifeSciences) and several key capital projects such as the Biomanufacturing Incubator (BMI) and the BioAccelerator. He served as an appointed member of the Canadian Health / BioScience Economic Strategy Table (HBEST), a federal initiative to get advice from the private sector for Canada’s future economic success.